Dr Reddy’s launches Treprostinil injection in US
City-based pharmaceutical company Dr Reddy’s Laboratories Limited on Friday announced the launch of Treprostinil Injection in the U S market.
image for illustrative purpose
Hyderabad: City-based pharmaceutical company Dr Reddy’s Laboratories Limited on Friday announced the launch of Treprostinil Injection in the U S market.
A therapeutic equivalent generic version of Remodulin, Treprostinil injection is approved by the U S Food and Drug Administration (USFDA). Dr Reddy’s new launch is supplied in 20 mg/20 ml, 50 mg/20 ml, 100 mg/20 ml or 200mg/20 ml vials.
Treprostinil injection is a prostacyclin mimetic indicated for patients who require transition from epoprostenol, to reduce the rate of clinical deterioration, the drug maker said. “It is used in treatment of pulmonary arterial hypertension to diminish symptoms associated with exercise,” it added.
Dr Reddy’s informing about studies establishing its effectiveness said, patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58 per cent), PAH associated with congenital systemic-to-pulmonary shunts (23 per cent), or PAH associated with connective tissue diseases (19 per cent).
